Experimental studies have shown that the overexpression of 11β-HSD1 exacerbates hepatic steatosis [45], while the pharmacological inhibition of this enzyme improves insulin sensitivity and reduces the hepatic triglyceride content. This evidence concerns the gene INS and fatty liver disease.